CRISPR Patents in Gene-Editing Lawsuit Knocked Out by Board (1)

An administrative tribunal axed two patents relating to CRISPR-related genome-editing technology being asserted in a parallel lawsuit in federal court in California.

The Patent Trial and Appeal Board canceled all every claim in Agilent Technolgoies Inc.'s US Patent Nos. 10,337,001 and 10,900,034 in response to challenges filed by Synthego Corp.

Agilent had accused Synthego of patent theft in a suit filed in the US District Court for the Northern District of California and is seeking to block sales of allegedly infringing CRISPR-related products.

The court paused the case, however, so that the PTAB could resolve the two validity challenges.

Each ...